尿液生物标志物检测膀胱癌的诊断效能:系统评价、Meta分析与网状Meta分析
该系统评价与Meta分析检索PubMed和Medline截至2025年9月30日的文献,纳入122项研究共24,252例患者,评估尿液诊断膀胱癌的准确性。新型尿液检测的合并灵敏度最高达90%、特异度最高达92%,网状Meta分析显示其诊断价值显著高于尿细胞学。
要点
- 新型尿液检测诊断膀胱癌合并灵敏度最高90%、特异度最高92%
- 网状Meta分析显示新型尿液检测诊断价值显著优于尿细胞学
- 多数研究在初发和复发膀胱癌评估中的偏倚风险不明确
核心结论
- 分析支持新型尿液膀胱癌检测具有较高诊断准确性。
- 网状Meta分析显示新型尿液检测的诊断价值显著高于尿细胞学。
研究设计与样本
- 系统评价、诊断试验准确性Meta分析与网状Meta分析,检索PubMed和Medline截至2025年9月30日。
- 定性合成纳入122项研究、共24,252例患者。
- 采用随机效应模型计算标志物合并灵敏度与特异度。
主要发现
- 新型尿液检测的合并灵敏度最高达90%,特异度最高达92%。
- 多数研究在初发和复发膀胱癌评估中的偏倚风险不明确。
关键数值与推荐
- 新型尿液检测合并灵敏度最高90%、特异度最高92%。
- 网状Meta分析示新型尿液检测诊断价值显著高于尿细胞学。
临床怎么用
- 可考虑将新型尿液检测用于膀胱癌的诊断评估。
- 解读结果时需注意多数研究偏倚风险不明确。
局限性
- 多数研究在初发和复发膀胱癌评估中的偏倚风险不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the diagnostic estimates of current urine-based diagnostic bladder tests for diagnosing bladder cancer using diagnostic test accuracy (DTA) and network meta-analysis (NMA). METHODS: The search for this systematic review and meta-analysis was conducted on PubMed and Medline for relevant studies published until September 30, 2025. The meta-analysis and network meta-analysis were performed using a random-effect model, to compute the pooled sensitivity and specificity of the markers. The qualitative synthesis included 122 studies comprising 24,252 patients. RESULTS: In most studies, there was an unclear risk of bias in the setting of evaluating de novo and recurrent bladder cancer. Novel urine-based assays demonstrated promising diagnostic values with pooled sensitivity upto 90% and specificity upto 92%. The NMA revealed that diagnostic values of the novel urine-based assays were significantly higher than those of cytology for detecting bladder cancer. CONCLUSION: Over the past decade, several new urine-based bladder cancer detection assays have become commercially available. Our analysis supports a high diagnostic accuracy of the newer urine-based bladder cancer detection tests for evaluating bladder cancer. PROSPERO REGISTRATION: CRD420251134193.
引用
- Siguencia F, Heard J, Smith SM, et al. Diagnostic Performance of Urinary Biomarker Tests in Detecting Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis. Urology. 2026. PMID: 41651230. doi:10.1016/j.urology.2026.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。